The V Foundation has awarded Mitchell Fane of Fox Chase Cancer Center a grant to advance aging-focused melanoma research, directing new funding toward a question dermatologic oncology has yet to answer convincingly: why melanoma behaves differently in older patients.

The award positions Fane's laboratory to examine the biological interface between the aging process and melanoma development and progression. Fox Chase Cancer Center announced the grant, which adds the institution to the roster of academic centers the V Foundation supports through its competitive translational research funding programs.

Aging stands among the strongest risk factors for melanoma. Median age at diagnosis sits in the mid-60s, and incidence rates in older adults continue to climb even as younger cohorts see slower growth. Yet most mechanistic research still draws on models and cell systems that do not account for the aged tumor microenvironment, leaving a gap between the demographics of the disease and the biology underpinning laboratory findings. Fane's funded work targets precisely that gap.

For dermatologists who manage older patients with melanoma, the research agenda carries practical weight. Tumor biology in the elderly may differ in ways that affect Breslow thickness at presentation, growth rate, and response to systemic therapy, and a mechanistic account of age-related differences could eventually inform surveillance intervals and treatment sequencing for this population. The grant signals that funders now prioritize geroscience questions within skin oncology rather than treating age as a mere covariate.

The V Foundation, established in memory of Jim Valvano, funds emerging and established investigators across cancer research, with a track record of backing high-risk, high-reward projects that traditional funding mechanisms often overlook. Grants of this type typically support early-stage translational work — the kind that generates the preclinical data needed to compete for larger National Cancer Institute awards.

Fox Chase, a National Cancer Institute-designated comprehensive cancer center in Philadelphia, has built its melanoma program around molecular characterization and immune-oncology approaches. Fane's aging-focused project extends that portfolio into tumor biology shaped by chronological age, a dimension that histopathology staging systems such as AJCC staging capture only indirectly through patient demographics.

Details of the funded project — its specific aims, model systems, timeline, and award amount — were not disclosed in the announcement. The center has not yet published the underlying protocol.

The field will watch whether Fane's work produces the kind of age-stratified mechanistic data that could shift how clinicians interpret melanoma risk and therapy response in the fastest-growing segment of the patient population.